- Posted Date: August 18, 2015
- Open Date (Earliest Submission Date): October 20, 2015
- Letter of Intent Due Date(s): 30 days before the application due date
- Application Due Date(s): November 20, 2015; June 14, 2016; November 21, 2016; June 14, 2017; November 20, 2017; June 14, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
- AIDS Application Due Date(s): Not Applicable
- Scientific Merit Review: March-April 2016, October-November 2016, March-April 2017, October-November 2017, March-April 2018, October-November 2018
- Advisory Council Review: May 2016, January 2017, May 2017, January 2018, May 2018, January 2019
- Earliest Start Date: July 2016, April 2017, July 2017, April 2018, July 2018, April 2019
The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included.